After some time in the making, I am really happy to announce @OverT_Bio’s official launch today. I am excited and humbled by the experience of building OverT with a terrific team of scientists and operators #startup#celltherapy#cancer
We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.
endpts.com/overt-bio-debuts-…
Excited to share a big milestone for OverT Bio—we’ve formed our Clinical Advisory Board.
Grateful to partner with an incredible group of leaders as we build scalable γδ CAR-T therapies for solid tumors.
businesswire.com/news/home/2…
Our team in #Barcelona is expanding & we're #hiring 2 talented scientists to fill these exciting new positions: a Lead Scientist & a Research Associate.
Do u want to make a real difference in the future of applied high-throughput genetics and therapeutics? #PhdChat#ScienceJobs
🎉Congratulations to the team at @OverT_Bio and its co-founders, @MatLegut and former CRI Tech Impact Award Grantee @nevillesanjana on the company's debut! Learn more in @endpts:
We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.
endpts.com/overt-bio-debuts-…
Congrats to @MatLegut & the entire @OverT_Bio team! Grateful for the opportunity to translate discoveries from our lab @nygenome & @nyuniversity into therapies for cancer patients.
Thrilled to be a part of this amazing team — onward and upward! 🚀
We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.
endpts.com/overt-bio-debuts-…
After some time in the making, I am really happy to announce @OverT_Bio’s official launch today. I am excited and humbled by the experience of building OverT with a terrific team of scientists and operators #startup#celltherapy#cancer
We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.
endpts.com/overt-bio-debuts-…
Last but not least, special mention to our first investors who supported us from the very start of this journey: Jim Magid, Dr. Anthony Evnin and Jeanette Cone Kimmel
We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.
endpts.com/overt-bio-debuts-…
Big news!! I can finally officially announce that a few weeks ago, ALLOX @ALLOXbio was co-founded by the brilliant André Faure @aj4re , Pablo Baeza @pbcenturion , Ben Lehner @BenLehner , and myself, who will be stepping in as CEO of the company.
A really exciting article, fresh from the press @CellCellPress! T cells are indeed #crossreactive, in this case a single T cell receptor can bind and recognise distinct cancer antigens from not one, but three proteins (or more!).
authors.elsevier.com/sd/arti…
Shoutout to @TcellResearch team for this beautiful study! Super happy to have been able to contribute a small part to this work. Hoping this discovery will bring about #tcr#celltherapy to more patients with hard to treat cancers! #immunotherapy
For anyone interested in our work and our team - we would greatly appreciate extra votes in the following competition! Voting is open until the 4th July 🗳️🙏🏻🧬🧪
MolecularCloud | 2023 Distinguished Research Awards for Gene and Cell Therapy molecularcloud.org/researcha…
Grateful for being invited to participate in the new Tools of the trade series from @NatureRevCancer, highlighting our recent study on developing new #immunotherapy for cancer through genome-scale screens in #tcells
Super excited to see our research on building new immunotherapies getting picked by @statnews to represent @nyuniversity
(Also, turns out this March Madness is like an actual sports thing! Things you learn… 🤷🏻♂️)
statnews.com/feature/stat-ma…